{"id":3820,"date":"2012-10-24T20:12:19","date_gmt":"2012-10-25T00:12:19","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=3820"},"modified":"2012-10-24T21:33:40","modified_gmt":"2012-10-25T01:33:40","slug":"united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820","title":{"rendered":"United Therapeutics Down 15% Following FDA\u2019s Rejection of Oral Remodulin (UTHR)"},"content":{"rendered":"<p>After the close of trading yesterday, biopharmaceutical company United Therapeutics (NASDAQ: UTHR) disclosed that its New Drug Application for an oral version of its lung disorder drug, Remodulin, was rejected by the FDA citing an inability to demonstrate patient improvement in Phase III studies. With such negative news, traders had no second thought and went on a selling spree right from the opening of today\u2019s trading session. The shares of United Therapeutics lost more than 14% in the first half hour of trading on a volume of more than 1.83 million shares.<\/p>\n<p>The Maryland-based company is engaged in the development of therapeutic products for patients with chronic and life-threatening diseases. The company\u2019s product line includes Remodulin, Tyvaso, and Adcirca for the treatment of pulmonary arterial hypertension (PAH). Remodulin, Tyvaso and Adcirca generate nearly $900 million in combined revenue per annum. The FDA had approved injectable Remodulin in 2002.<\/p>\n<p>On December 2011, United Therapeutics filed a New Drug Application for the oral formulation of Remodulin, which is chemically known as treprostinil diethanolamine. Also in December 2011, Martine Rothblatt, CEO of United Therapeutics, <a href=\"http:\/\/www.forbes.com\/sites\/dividendchannel\/2011\/12\/15\/top-buys-by-top-brass-ceo-rothblatts-2-7m-bet-on-uthr\/?partner=yahootix\">invested $2.7 million<\/a> in the company\u2019s shares. The news instilled confidence in the market, thereby resulting in a rise in the share price to $48.76 on January 10. Two days later, an upgrade from <a href=\"http:\/\/www.thestreet.com\/_yahoo\/story\/11374273\/1\/united-therapeutics-gets-upgrade-on-revenue-growth.html?cm_ven=YAHOO&amp;cm_cat=FREE&amp;cm_ite=NA\">The Street Ratings<\/a>\u00a0to \u201cbuy\u201d from \u201chold\u201d took United Therapeutics\u2019 share price to $50.99 on February 6. By mid-March, United Therapeutics filed <a href=\"http:\/\/finance.yahoo.com\/news\/uthr-files-suit-vs-sandoz-223523586.html\">patent infringement lawsuit<\/a> against Sandoz, Novartis<em>\u2019<\/em> (NYSE: NVS) generic unit, which is seeking approval for its generic version of Remodulin. The event was followed by a decline in the share price of United Therapeutics to $40.42 on April 18. A <a href=\"http:\/\/seekingalpha.com\/article\/638161-4-reasons-to-buy-united-therapeutics?source=yahoo\">Seeking Alpha report<\/a> published on June 5 recommending United Therapeutics and the news of the\u00a0<a href=\"http:\/\/www.bizjournals.com\/triangle\/morning_call\/2012\/06\/united-therapeutics-buys-rtp-buildings.html?ana=yfcpc\">purchase of RTP buildings<\/a> from GlaxoSmithkline (NYSE: GSK) by United Therapeutics on June 29 aided the share price to reach $52.00 by the first week of July 2012.<\/p>\n<p>The fiscal 2012 second-quarter earnings <a href=\"http:\/\/finance.yahoo.com\/news\/uthr-beats-higher-revs-115942129.html\">beat the Zacks consensus estimate<\/a> and lifted the share price of United Therapeutics to $56.78 by August 15. With a reiteration of the \u201coutperform\u201d rating from Zacks Equity Research on September 28, the share price touched $58.91 on October 2.<\/p>\n<p>Two days prior, The Street published a report indicating the <a href=\"http:\/\/www.thestreet.com\/story\/11742963\/1\/united-therapeutics-could-lose-the-battle-for-pah-therapies.html?puc=yahoo&amp;cm_ven=YAHOO\">possibility of a FDA decision<\/a> that might go against the United Therapeutics\u2019 interests. The FDA letter to United Therapeutics questioned the clinical importance of the 6 Minute Walk Distance (6MWD) effect size shown in the FREEDOM-M study. The <a href=\"http:\/\/finance.yahoo.com\/news\/united-therapeutics-announces-receipt-complete-201500283.html\">FDA also pointed out<\/a> that it was unsure whether an additional clinical study could alter the impressions.<\/p>\n<p>Commenting on the rejection, Martine Rothblatt, Chairman and CEO of United Therapeutics, stated, \u201cWe will continue using our best efforts to gain approval of oral treprostinil, and we will focus on doing so within the next four years.\u201d The shares of United Therapeutics fell as much as 16% in extended trading yesterday.<\/p>\n<p>United Therapeutics ended the day at $44.99 per share, down $8.29 or 15.6% on a volume of 4.48 million shares.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>After the close of trading yesterday, biopharmaceutical company United Therapeutics (NASDAQ: UTHR) disclosed that its New Drug Application for an oral version of its lung [&hellip;]<\/p>\n","protected":false},"author":12,"featured_media":3843,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[261,264,4],"tags":[155,493,456],"stock_ticker":[],"class_list":["post-3820","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-decliners","category-health","category-nasdaq-high-profiles","tag-gsk","tag-nvs","tag-uthr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>United Therapeutics Down 15% Following FDA\u2019s Rejection of Oral Remodulin (UTHR) - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"United Therapeutics Down 15% Following FDA\u2019s Rejection of Oral Remodulin (UTHR) - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"After the close of trading yesterday, biopharmaceutical company United Therapeutics (NASDAQ: UTHR) disclosed that its New Drug Application for an oral version of its lung [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2012-10-25T00:12:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2012-10-25T01:33:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/10\/Screen-Shot-2012-10-24-at-8.48.38-PM.png\" \/>\n\t<meta property=\"og:image:width\" content=\"552\" \/>\n\t<meta property=\"og:image:height\" content=\"268\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Steve Hackney\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Steve Hackney\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820\"},\"author\":{\"name\":\"Steve Hackney\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867\"},\"headline\":\"United Therapeutics Down 15% Following FDA\u2019s Rejection of Oral Remodulin (UTHR)\",\"datePublished\":\"2012-10-25T00:12:19+00:00\",\"dateModified\":\"2012-10-25T01:33:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820\"},\"wordCount\":487,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/10\/Screen-Shot-2012-10-24-at-8.48.38-PM.png\",\"keywords\":[\"GSK\",\"NVS\",\"UTHR\"],\"articleSection\":[\"Decliners\",\"Health\",\"NASDAQ high profiles\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820\",\"name\":\"United Therapeutics Down 15% Following FDA\u2019s Rejection of Oral Remodulin (UTHR) - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/10\/Screen-Shot-2012-10-24-at-8.48.38-PM.png\",\"datePublished\":\"2012-10-25T00:12:19+00:00\",\"dateModified\":\"2012-10-25T01:33:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/10\/Screen-Shot-2012-10-24-at-8.48.38-PM.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/10\/Screen-Shot-2012-10-24-at-8.48.38-PM.png\",\"width\":552,\"height\":268},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"United Therapeutics Down 15% Following FDA\u2019s Rejection of Oral Remodulin (UTHR)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867\",\"name\":\"Steve Hackney\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g\",\"caption\":\"Steve Hackney\"},\"description\":\"Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/steve-hackney\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"United Therapeutics Down 15% Following FDA\u2019s Rejection of Oral Remodulin (UTHR) - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820","og_locale":"en_US","og_type":"article","og_title":"United Therapeutics Down 15% Following FDA\u2019s Rejection of Oral Remodulin (UTHR) - Wall Street PR","og_description":"After the close of trading yesterday, biopharmaceutical company United Therapeutics (NASDAQ: UTHR) disclosed that its New Drug Application for an oral version of its lung [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2012-10-25T00:12:19+00:00","article_modified_time":"2012-10-25T01:33:40+00:00","og_image":[{"width":552,"height":268,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/10\/Screen-Shot-2012-10-24-at-8.48.38-PM.png","type":"image\/png"}],"author":"Steve Hackney","twitter_misc":{"Written by":"Steve Hackney","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820"},"author":{"name":"Steve Hackney","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867"},"headline":"United Therapeutics Down 15% Following FDA\u2019s Rejection of Oral Remodulin (UTHR)","datePublished":"2012-10-25T00:12:19+00:00","dateModified":"2012-10-25T01:33:40+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820"},"wordCount":487,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/10\/Screen-Shot-2012-10-24-at-8.48.38-PM.png","keywords":["GSK","NVS","UTHR"],"articleSection":["Decliners","Health","NASDAQ high profiles"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820","url":"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820","name":"United Therapeutics Down 15% Following FDA\u2019s Rejection of Oral Remodulin (UTHR) - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/10\/Screen-Shot-2012-10-24-at-8.48.38-PM.png","datePublished":"2012-10-25T00:12:19+00:00","dateModified":"2012-10-25T01:33:40+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/10\/Screen-Shot-2012-10-24-at-8.48.38-PM.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/10\/Screen-Shot-2012-10-24-at-8.48.38-PM.png","width":552,"height":268},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-down-15-following-fdas-rejection-of-oral-remodulin-uthr-3820#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"United Therapeutics Down 15% Following FDA\u2019s Rejection of Oral Remodulin (UTHR)"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867","name":"Steve Hackney","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g","caption":"Steve Hackney"},"description":"Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/steve-hackney"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/3820","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=3820"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/3820\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/3843"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=3820"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=3820"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=3820"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=3820"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}